Romosozumab and antiresorptive treatment: the importance of treatment sequence.
Felicia CosmanDavid L KendlerBente L LangdahlBenjamin Z LederE Michael LewieckiAkimitsu MiyauchiMaria RojeskiMichele McDermottMary K OatesCassandra E MilmontCesar LibanatiSerge FerrariPublished in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2022)
In this study, larger mean BMD increases and greater BMD responder rates were achieved when romosozumab was used before, versus after, an antiresorptive agent. Since BMD on treatment is a strong surrogate for bone strength and fracture risk, this analysis supports the thesis that initial treatment with romosozumab followed by an antiresorptive will result in greater efficacy versus the reverse sequence.
Keyphrases